BACKGROUND The German Health Data Utilization Act and the Digitization Act aim to enhance health data sharing for healthcare and research in Germany and beyond, while ensuring robust data protection. In light of the opt-out regulation, a key prerequisite for using these data is the willingness of patients to share their data for primary use (PU), eg medical care and secondary use (SU), eg research. Qualitative research is needed to determine patients’ perspectives regarding data sharing, especially in vulnerable groups like those with mental health diseases. However, there is a lack of qualitative research comparing data sharing perspectives between patients with somatic and mental health diseases under the new legal framework.
OBJECTIVE This study qualitatively examines the factors influencing German patients’ willingness to share their digital health data for PU and SU, exploring similarities and differences between patients with somatic and mental health diseases.
METHODS In 2024, two focus groups (FGs) were conducted with 13 patients undergoing outpatient treatment: seven with somatic diseases (FG1) and six with mental health diseases (FG2). Participants were recruited from the University Hospital in Dresden, Germany, based on predefined inclusion criteria. The FG discussions followed a topic guide with open-ended questions based on an overview of reviews and pretests. Data were qualitatively analyzed by two researchers independently according to Kuckartz’ approach. The findings are reported according to the COREQ checklist for qualitative research.
RESULTS Ten main categories and 32 subcategories were identified. Participants from both FGs highlighted individual usefulness for medical care and comprehensive public benefits despite various personal experiences. Fears of discrimination and stigmatization and data security concerns about automatic data sharing were more relevant in FG2. Technical safety measures of anonymization and pseudonymization were discussed in detail in FG1, while FG2 debated data protection intensively. There were concerns that data protection in Germany could potentially pose a greater health risk than the sharing of personal health data. The category consent management preferences yielded the most statements, but no clear consensus emerged. Social influence and involvement, including family, peers, and healthcare professionals, were more relevant in FG2. Both FGs explicitly opposed the use of health data by technology companies like Google.
CONCLUSIONS Our study compares the perspectives of patients with somatic and mental health diseases. While it revealed similarities, patients with mental health diseases viewed their data as highly sensitive due to experiences of stigmatization and fears of misuse, emphasizing the need for tailored consent management. Involving family, peers, and healthcare professionals can increase acceptance. Healthcare professionals and targeted outreach can ensure transparency, raising awareness about data sharing policies to build trust, especially when commercial interests are involved. Knowledge deficits, even among tech-savvy patients, indicate the need for broad and understandable public relations efforts.